diversification.com

BGNE

Companies
NASDAQ
BeiGene, Ltd.
Health Care
OverviewNewsRisk & CorrelationForecasts
Price Chart
Overview

About BGNE

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Market Cap
$16.3B
Volume
207.1M
Avg. Volume
127.1M
P/E Ratio
-143.18605
Dividend Yield
0.00%
Employees
7.7K

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Latest News for BGNE
Risk & Correlation Analysis
Market Correlation
0.92
Moderate Correlation
Volatility
High (0.45)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for BGNE.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, BGNE shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$16.3B
Volume207.1M
P/E Ratio-143.19
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
November 10, 2023
Related Securities
ARKG
ARK Genomic Revolution ETF
IBB
iShares Biotechnology ETF
XBI
SPDR S&P Biotech ETF
BNTX
BioNTech SE - American Depositary Receipt
MRNA
Moderna Inc.
ILMN
Illumina, Inc.
REGN
Regeneron Pharmaceuticals, Inc.

PortfolioPilot Analysis

Get AI-powered insights on how BGNE fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025